Aris Global and Medidata Solutions Partner to Offer Integation of EDC and Safety Reporting
Clinical trial technology companies Medidata Solutions and Aris Global announced the availability of an integrated solution that provides data-sharing between the Medidata Rave® system for electronic data capture, management and reporting and ARISg™, a solution for pharmacovigilance and clinical safety. The solution leverages Medidata’s Rave Safety Gateway, a configurable EDC-to-Safety system interface, to automatically transmit safety-related patient data collected in Medidata Rave directly into ARISg to help reduce risk, redundant data entry and eliminate the costly and time-sensitive burden of collecting and reconciling safety data.
“While Aris Global offers agCapture™, an EDC solution, we also see the value in giving customers the opportunity to leverage the Rave Safety Gateway to address their critical business challenges. The combined use of ARISg and Medidata Rave, leveraging Rave Safety Gateway, addresses the time-sensitive and safety-critical process of alerting regulatory agencies to potential safety events,” said Jeffrey Yablon, Vice President, Sales Aris Global.
A key purpose of clinical trials, as well as being a major obligation of the sponsor, is to monitor patients for serious adverse events (SAEs) and to collect and transmit reports in a timely manner. Even today, much of the collection of that data takes place outside other automated processes in a clinical trial, such as EDC systems like Medidata Rave. The traditional process involves phone conversations, paper forms and faxes between sites and sponsors, as well as manual keying of data into the sponsors’ safety system like ARISg, which helps collect, code, analyze and submit the information to regulatory agencies and license partners on a timely basis.
By instantly transferring safety-related data from the Medidata Rave EDC system to the ARISg safety reporting system, this solution helps eliminate duplicative entry, reduce SAE reconciliation efforts and chances for errors and expedite reporting time.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
